NYSE : HLN
Haleon plc — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United Kingdom
Last price 8.57 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 37.43B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 37.69B |
| Enterprise Value | 47.72B |
Dates
| Measure | Value |
|---|
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | Aug 14, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 8.89B |
| Shares Change (YoY) | -1.66% |
| Shares Change (QoQ) | -0.76% |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 94.26% |
| Float | 8.78B |
Ratios
| Measure | Value |
|---|
| PE Ratio | 17.86 |
| Forward PE | 15.14 |
| PS Ratio | 2.55 |
| Forward PS | 4.94 |
| PB Ratio | 1.73 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 12.16 |
| P/OCF Ratio | 10.62 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 22.16 |
| EV / Sales | 3.23 |
| EV / EBITDA | 12.63 |
| EV / EBIT | 13.74 |
| EV / FCF | 15.40 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.69 |
| Quick Ratio | 0.51 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | 2.84 |
| Debt / FCF | 3.53 |
| Interest Coverage | 8.08 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 10.09% |
| Return on Assets (ROA) | 5.08% |
| Return on Invested Capital (ROIC) | 8.42% |
| Return on Capital Employed (ROCE) | 9.94% |
| Weighted Average Cost of Capital (WACC) | 5.18% |
| Revenue Per Employee | $603,071 |
| Profits Per Employee | $87,768 |
| Employee Count | 24,535 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 3.49 |
Taxes
| Measure | Value |
|---|
| Income Tax | 658.09M |
| Effective Tax Rate | 23.25% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.28 |
| 52-Week Price Change | -4.31% |
| 50-Day Moving Average | 9.54 |
| 200-Day Moving Average | 9.77 |
| Relative Strength Index (RSI) | 33.05 |
| Average Volume (20 Days) | 19,048,075 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 18.54M |
| Short Previous Month | 21.80M |
| Short % of Shares Out | 0.42% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.88 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 14.80B |
| Gross Profit | 9.70B |
| Operating Income | 3.47B |
| Pretax Income | 2.83B |
| Net Income | 2.15B |
| EBITDA | 3.78B |
| EBIT | 3.47B |
| Earnings Per Share (EPS) | $0.48 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.10B |
| Total Debt | 10.95B |
| Net Cash | -9.85B |
| Net Cash Per Share | -$1.11 |
| Equity (Book Value) | 21.81B |
| Book Value Per Share | 2.45 |
| Working Capital | -2.59B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 3.55B |
| Capital Expenditures | -449.84M |
| Depreciation & Amortization | 307.92M |
| Net Borrowing | -629.24M |
| Free Cash Flow | 3.10B |
| FCF Per Share | $0.35 |
Margins
| Measure | Value |
|---|
| Gross Margin | 65.57% |
| Operating Margin | 23.48% |
| Pretax Margin | 19.13% |
| Profit Margin | 14.55% |
| EBITDA Margin | 25.54% |
| EBIT Margin | 23.48% |
| FCF Margin | 20.76% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $0.20 |
| Dividend Yield | 2.29% |
| Dividend Growth (YoY) | 7.41% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 40.82% |
| FCF Payout Ratio | 56.73% |
| Buyback Yield | 1.66% |
| Shareholder Yield | 3.95% |
| Earnings Yield | 5.60% |
| FCF Yield | 8.22% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $11.59 |
| Price Target Difference | 33.83% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 3.48% |
| EPS Growth Forecast (3Y) | 8.69% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.92 |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |